PCRX Downgraded by Jefferies -- Rating Changed to Hold
Pacira BioSciences (PCRX) was downgraded by Jefferies from Buy to Hold with a $36.00 price target. The stock is currently trading at $36.39, which is 23.9% above its GF Value of $29.38, indicating overvaluation. The company has a GF Score of 83/100, showing strong performance in profitability and growth but concerns about valuation. Insiders have sold shares worth $70,619 in the last three months, suggesting cautious sentiment.
How this was made
The 30-second read
Why it matters
Analyst downgrade adds a negative catalyst, likely prompting short‑term price correction toward the $36 target.
Market read
The downgrade is the primary new information, offering a clear short‑term trading signal for PCRX.
What to watch
Potential pipeline developments or upcoming trial data could offset the downgrade.
Background
PCRX trades at a premium to its GuruFocus intrinsic value, with a trailing P/E of 105 versus a 5‑year median of 73.
Ticker impact
Jefferies downgraded Pacira BioSciences to Hold and set a $36 price target, indicating a fresh negative analyst view.
downward pressure as investors price in the Hold rating and lower target
Analyst rating changes are primary news; the new target is below current price, prompting potential exits.
Market effects
May weigh on other specialty pharma stocks as analysts reassess valuation multiples.
Limited to U.S. biotech sector; no broader regional effect.
Low global impact; primarily relevant to U.S. investors in PCRX.
Counterpoint
Some investors may view the Hold rating as a buying opportunity if they believe the overvaluation is temporary.
Key entities
- analystJefferies
Equity research firm that issued the downgrade.
- companyPacira BioSciences
Specialty pharmaceutical company focused on non‑opioid pain management.
